Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis

Clifford Folmes, Alexander S. Clanachan, Gary D. Lopaschuk

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

Ischemic heart disease is characterized by a modification of the normal energy balance of the heart. During and following an ischemic event, circulating fatty acids are elevated, resulting in the acceleration of fatty acid oxidation at the expense of glucose oxidation. Despite the reduction in glucose oxidation, the rate of glycolysis increases, leading to an uncoupling of glucose metabolism. This results in the accumulation of metabolic byproducts, which leads to a decrease in cardiac efficiency. A novel therapeutic strategy involves improving the efficiency of oxygen utilization by the ischemic heart by the modulation of energy metabolism. This can be achieved by a reduction in the levels of circulating fatty acids using β-blockers, glucose-insulin-potassium infusions, and nicotinic acid. Alternatively, fatty acid oxidation can be directly inhibited using trimetazidine, ranolazine, or glucose oxidation directly activated using dichloroacetate, which significantly improves the efficiency of the heart.

Original languageEnglish (US)
Pages (from-to)63-70
Number of pages8
JournalCurrent Atherosclerosis Reports
Volume7
Issue number1
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Atherosclerosis
Fatty Acids
Glucose
Trimetazidine
Niacin
Glycolysis
Energy Metabolism
Myocardial Ischemia
Potassium
Insulin
Oxygen
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis. / Folmes, Clifford; Clanachan, Alexander S.; Lopaschuk, Gary D.

In: Current Atherosclerosis Reports, Vol. 7, No. 1, 01.01.2005, p. 63-70.

Research output: Contribution to journalReview article

@article{2facd1f1bb4c4d6496c0ad64353f504c,
title = "Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis",
abstract = "Ischemic heart disease is characterized by a modification of the normal energy balance of the heart. During and following an ischemic event, circulating fatty acids are elevated, resulting in the acceleration of fatty acid oxidation at the expense of glucose oxidation. Despite the reduction in glucose oxidation, the rate of glycolysis increases, leading to an uncoupling of glucose metabolism. This results in the accumulation of metabolic byproducts, which leads to a decrease in cardiac efficiency. A novel therapeutic strategy involves improving the efficiency of oxygen utilization by the ischemic heart by the modulation of energy metabolism. This can be achieved by a reduction in the levels of circulating fatty acids using β-blockers, glucose-insulin-potassium infusions, and nicotinic acid. Alternatively, fatty acid oxidation can be directly inhibited using trimetazidine, ranolazine, or glucose oxidation directly activated using dichloroacetate, which significantly improves the efficiency of the heart.",
author = "Clifford Folmes and Clanachan, {Alexander S.} and Lopaschuk, {Gary D.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1007/s11883-005-0077-2",
language = "English (US)",
volume = "7",
pages = "63--70",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis

AU - Folmes, Clifford

AU - Clanachan, Alexander S.

AU - Lopaschuk, Gary D.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Ischemic heart disease is characterized by a modification of the normal energy balance of the heart. During and following an ischemic event, circulating fatty acids are elevated, resulting in the acceleration of fatty acid oxidation at the expense of glucose oxidation. Despite the reduction in glucose oxidation, the rate of glycolysis increases, leading to an uncoupling of glucose metabolism. This results in the accumulation of metabolic byproducts, which leads to a decrease in cardiac efficiency. A novel therapeutic strategy involves improving the efficiency of oxygen utilization by the ischemic heart by the modulation of energy metabolism. This can be achieved by a reduction in the levels of circulating fatty acids using β-blockers, glucose-insulin-potassium infusions, and nicotinic acid. Alternatively, fatty acid oxidation can be directly inhibited using trimetazidine, ranolazine, or glucose oxidation directly activated using dichloroacetate, which significantly improves the efficiency of the heart.

AB - Ischemic heart disease is characterized by a modification of the normal energy balance of the heart. During and following an ischemic event, circulating fatty acids are elevated, resulting in the acceleration of fatty acid oxidation at the expense of glucose oxidation. Despite the reduction in glucose oxidation, the rate of glycolysis increases, leading to an uncoupling of glucose metabolism. This results in the accumulation of metabolic byproducts, which leads to a decrease in cardiac efficiency. A novel therapeutic strategy involves improving the efficiency of oxygen utilization by the ischemic heart by the modulation of energy metabolism. This can be achieved by a reduction in the levels of circulating fatty acids using β-blockers, glucose-insulin-potassium infusions, and nicotinic acid. Alternatively, fatty acid oxidation can be directly inhibited using trimetazidine, ranolazine, or glucose oxidation directly activated using dichloroacetate, which significantly improves the efficiency of the heart.

UR - http://www.scopus.com/inward/record.url?scp=15444361805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15444361805&partnerID=8YFLogxK

U2 - 10.1007/s11883-005-0077-2

DO - 10.1007/s11883-005-0077-2

M3 - Review article

VL - 7

SP - 63

EP - 70

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 1

ER -